ClinicalTrials.gov: NCT07567001 (HF-POLARIS) | Mechanism: GLP-1 / amylin dual agonist TRIAL SPOTLIGHT Educational spotlight selected by editors Semaglutide Without the Needle: A Dissolving Microarray Patch Enters the Clinic Terrestrial Bio (formerly Vaxess Technologies) dosed the first patients on July 1, 2026, in a Phase 1 trial (NCT07673900) evaluating VX-201, a needle-free microarray patch branded as Tacterra that delivers the established GLP-1 receptor agonist semaglutide
For instance, in the SURPASS-4 trial, where tirzepatide was compared with insulin glargine in patients with T2DM and a high cardiovascular risk, 15 mg of tirzepatide reduced the levels of TC, LDL-C, and TGs by 5.6%, 7.9%, and 22.5%, respectively, and increased the levels of HDL-C by 10.8%
They can help determine whether a semaglutide dosage or tirzepatide dosage (Ozempic, Wegovy, Zepbound and Mounjaro) adjustment is necessary, or if other factors are affecting your progress
Additionally, oral supplements require daily adherence to maintain consistent levels, which can be a challenge for some people
